Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Alzheimer's Disease

  Free Subscription

Articles published in Lancet Neurol

Retrieve available abstracts of 43 articles:
HTML format

Single Articles

    May 2022
  1. OSSENKOPPELE R, van der Kant R, Hansson O
    Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Lancet Neurol. 2022 May 25. pii: S1474-4422(22)00168.
    PubMed     Abstract available

    April 2022
  2. MORENAS-RODRIGUEZ E, Li Y, Nuscher B, Franzmeier N, et al
    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Lancet Neurol. 2022;21:329-341.
    PubMed     Abstract available

  3. SMIRNOV D, Galasko D
    Dynamics of neuroinflammation in Alzheimer's disease.
    Lancet Neurol. 2022;21:297-298.

    February 2022
  4. CHHATWAL JP, Schultz SA, McDade E, Schultz AP, et al
    Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Lancet Neurol. 2022;21:140-152.
    PubMed     Abstract available

  5. FRISONI GB, Lathuiliere A
    From patients to disease: the difficult case of Alzheimer's.
    Lancet Neurol. 2022;21:105-106.

    January 2022
    2021 marks a new era for Alzheimer's therapeutics.
    Lancet Neurol. 2022;21:3-4.

    December 2021
  7. MEAD S, Evans T
    Safe laboratory management of prions and proteopathic seeds.
    Lancet Neurol. 2021;20:981.

    November 2021
  8. TEUNISSEN CE, Verberk IMW, Thijssen EH, Vermunt L, et al
    Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
    Lancet Neurol. 2021 Nov 24. pii: S1474-4422(21)00361.
    PubMed     Abstract available

  9. FORTEA J, Zaman SH, Hartley S, Rafii MS, et al
    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
    Lancet Neurol. 2021;20:930-942.
    PubMed     Abstract available

  10. KEHOE PG, Turner N, Howden B, Jarutyte L, et al
    Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2021;20:895-906.
    PubMed     Abstract available

    The link between blood pressure and Alzheimer's disease.
    Lancet Neurol. 2021;20:878-879.

    September 2021
  12. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    PubMed     Abstract available

  13. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.

    August 2021
  14. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    PubMed     Abstract available

  15. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.

  16. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    PubMed     Abstract available

    July 2021
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.

  18. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    PubMed     Abstract available

    April 2021
  19. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    PubMed     Abstract available

    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.

    March 2021
  21. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    PubMed     Abstract available

    January 2021
  22. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    PubMed     Abstract available

  23. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.

    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.

    November 2020
  25. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    PubMed     Abstract available

  26. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.

    October 2020
  27. CONDELLO C, DeGrado WF, Prusiner SB
    Prion biology: implications for Alzheimer's disease therapeutics.
    Lancet Neurol. 2020;19:802-803.

  28. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    PubMed     Abstract available

    July 2020
  29. KELLAR D, Craft S
    Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.
    Lancet Neurol. 2020 Jul 27. pii: S1474-4422(20)30231.
    PubMed     Abstract available

    June 2020
  30. QUIROZ YT, Zetterberg H, Reiman EM, Chen Y, et al
    Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.
    Lancet Neurol. 2020;19:513-521.
    PubMed     Abstract available

    Major risk factors for Alzheimer's disease: age and genetics.
    Lancet Neurol. 2020;19:475-476.

    May 2020
  32. KARIKARI TK, Pascoal TA, Ashton NJ, Janelidze S, et al
    Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Lancet Neurol. 2020;19:422-433.
    PubMed     Abstract available

  33. MD JH
    Can we trust The End of Alzheimer's?
    Lancet Neurol. 2020;19:389-390.

  34. JACK CR JR
    The transformative potential of plasma phosphorylated tau.
    Lancet Neurol. 2020;19:373-374.

    April 2020
  35. MCMANUS RM, Heneka MT
    T cells in Alzheimer's disease: space invaders.
    Lancet Neurol. 2020;19:285-287.

    March 2020
  36. JESSEN F, Amariglio RE, Buckley RF, van der Flier WM, et al
    The characterisation of subjective cognitive decline.
    Lancet Neurol. 2020;19:271-278.
    PubMed     Abstract available

    February 2020
    A resurrection of aducanumab for Alzheimer's disease.
    Lancet Neurol. 2020;19:111-112.

  38. CRYAN JF, O'Riordan KJ, Sandhu K, Peterson V, et al
    The gut microbiome in neurological disorders.
    Lancet Neurol. 2020;19:179-194.
    PubMed     Abstract available

    January 2020
  39. ANDREWS SJ, Fulton-Howard B, Goate A
    Interpretation of risk loci from genome-wide association studies of Alzheimer's disease.
    Lancet Neurol. 2020 Jan 24. pii: S1474-4422(19)30435.
    PubMed     Abstract available

  40. JACK CR JR
    Preclinical Alzheimer's disease: a valid concept.
    Lancet Neurol. 2020;19:31.

  41. PETERS R, Anderson CS
    Advancing dementia prevention through effective blood pressure control.
    Lancet Neurol. 2020;19:25-27.

    November 2019
  42. DING J, Davis-Plourde KL, Sedaghat S, Tully PJ, et al
    Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies.
    Lancet Neurol. 2019 Nov 6. pii: S1474-4422(19)30393.
    PubMed     Abstract available

    August 2019
  43. LANE CA, Barnes J, Nicholas JM, Sudre CH, et al
    Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.
    Lancet Neurol. 2019 Aug 20. pii: S1474-4422(19)30228.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.